Toll-like receptors regulate B cell cytokine production in patients with diabetes

Department of Pathology, Boston University School of Medicine, Boston, MA, USA.
Diabetologia (Impact Factor: 6.88). 04/2010; 53(7):1461-71. DOI: 10.1007/s00125-010-1730-z
Source: PubMed

ABSTRACT Understanding cellular and molecular events in diabetes mellitus will identify new approaches for therapy. Immune system cells are important modulators of chronic inflammation in diabetes mellitus, but the role of B cells is not adequately studied. The aim of this work was to define the function of B cells in diabetes mellitus patients through focus on B cell responses to pattern recognition receptors.
We measured expression and function of Toll-like receptors (TLRs) on peripheral blood B cells from diabetes mellitus patients by flow cytometry and multiplexed cytokine analysis. We similarly analysed B cells from non-diabetic donors and periodontal disease patients as comparative cohorts.
B cells from diabetes mellitus patients secrete multiple pro-inflammatory cytokines, and IL-8 production is significantly elevated in B cells from diabetic patients compared with those from non-diabetic individuals. These data, plus modest elevation of TLR surface expression, suggest B cell IL-8 hyperproduction is a cytokine-specific outcome of altered TLR function in B cells from diabetes mellitus patients. Altered TLR function is further evidenced by demonstration of an unexpected, albeit modest 'anti-inflammatory' function for TLR4. Importantly, B cells from diabetes mellitus patients fail to secrete IL-10, an anti-inflammatory cytokine implicated in inflammatory disease resolution, under a variety of TLR-stimulating conditions. Comparative analyses of B cells from patients with a second chronic inflammatory disease, periodontal disease, indicated that some alterations in B cell TLR function associate specifically with diabetes mellitus.
Altered TLR function in B cells from diabetes mellitus patients increases inflammation by two mechanisms: elevation of pro-inflammatory IL-8 and lack of anti-inflammatory/protective IL-10 production.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipid accumulation in obesity triggers a low-grade inflammation that results from an imbalance between pro- and anti-inflammatory components of the immune system and acts as the major underlying mechanism for the development of obesity-associated diseases, notably insulin resistance and type 2 diabetes. Innate-like B cells are a subgroup of B cells that respond to innate signals and modulate inflammatory responses through production of immunomodulatory mediators such as the anti-inflammatory cytokine IL-10. In this study, we examined innate-like B cells in visceral white adipose tissue (VAT) and the relationship of these cells with their counterparts in the peritoneal cavity and spleen during diet-induced obesity (DIO) in mice. We show that a considerable number of innate-like B cells bearing a surface phenotype distinct from the recently identified "adipose natural regulatory B cells" populate VAT of lean animals, and that spleen represents a source for the recruitment of these cells in VAT during DIO. However, demand for these cells in the expanding VAT outpaces their recruitment during DIO, and the obese environment in VAT further impairs their function. We further show that removal of splenic precursors of innate-like B cells through splenectomy exacerbates, whereas supplementation of these cells via adoptive transfer ameliorates, DIO-associated insulin resistance. Additional adoptive transfer experiments pointed toward a dominant role of IL-10 in mediating the protective effects of innate-like B cells against DIO-induced insulin resistance. These findings identify spleen-supplied innate-like B cells in VAT as previously unrecognized players and therapeutic targets for obesity-associated diseases.
    Proceedings of the National Academy of Sciences 10/2014; 111(43). DOI:10.1073/pnas.1324052111 · 9.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is now accepted that metabolic disorders such as type 2 diabetes (T2D) and obesity are characterized by alterations in immune cells. Indeed, immune cells have been shown to play a critical role in fuel-ing the inflammation that accompanies increased fat deposition and insulin resistance. Both the innate (macrophages) and the adaptive arm (CD4 and CD8 T cells, in particular) significantly contribute to the chronic inflammatory state that characterizes these conditions. B cells, however , have until recently remained significantly understudied. This is not due to the fact that they do not play as significant a role, as more recent publications appear to show. Here, we briefly review the most recent literature and highlight the remaining outstanding questions. A CROSS TALK BETWEEN B CELLS AND ADIPOCYTES? B lymphocytes or B cells are the arm of the adaptive immune system responsible for the generation of antibodies. In addition , they produce cytokines that support the activation of other immune cells (1). Whether they interact and influence the physiology or pathophysiology of other non-immune cells, such as adipocytes in obesity, is only now beginning to emerge. Adipocytes themselves secrete cytokines also secreted by immune cells, such as TNFα, IL-6, and IL-8 (2). However, adipocytes secrete cytokines at significantly lower levels than the immune cells infiltrating adipose tissue in obesity (2). Adipocytes also secrete adipocyte-specific cytokines known as adipokines, these include lep-tin, adiponectin, resistin, which are also altered in obesity (3). The receptors for both leptin and adiponectin have been found on B cells; however, their role is still not understood. There is some evidence that leptin induces secretion of IL-10, IL-6, and TNFα in human B cells (4). However, how adipokines affect B cells and whether this plays a role in obesity has not been sufficiently addressed yet.
    Frontiers in Immunology 02/2015; 6:1-4. DOI:10.3389/fimmu.2015.00080
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes (T2D) is a metabolic disease associated with obesity-related insulin resistance (IR) and chronic inflammation. Animal studies indicate that IR can be caused and/or exacerbated by systemic and/or tissue-specific alterations in lymphocyte differentiation and function. Human studies also indicate that obesity-associated inflammation promotes IR. Nevertheless, clinical trials with anti-inflammatory therapies have yielded modest impacts on established T2D. Unlike mouse models, where obesity is predominantly associated with IR, 20-25% of obese humans are metabolically healthy with high insulin sensitivity. The uncoupling of obesity from IR in humans but not in animal models advocates for a more comprehensive understanding of mediators and mechanisms of human obesity-promoted IR, and better integration of knowledge from human studies into animal experiments to efficiently pursue T2D prevention and treatment. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Trends in Endocrinology and Metabolism 01/2015; 26(2). DOI:10.1016/j.tem.2014.12.001 · 8.87 Impact Factor


Available from
May 31, 2014